Descripción de la empresa
Orthofix Medical Inc. operates as a medical technology firm with a global footprint spanning the United States, Italy, the United Kingdom, France, Germany, Brazil, and international markets. The company's operations are divided into two primary segments: Global Spine and Global Limb Reconstruction, focusing on advanced medical device solutions. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, a space characterized by high regulatory standards and specialized technological requirements. With a market capitalization of $461.66M and annual revenue reaching $822.31M, the company demonstrates a significant operational scale supported by a workforce of 1605 employees. These valuation and revenue figures position Orthofix as a mid-cap player in the medical device landscape, indicating a substantial presence that allows for diversified product offerings across multiple geographies while maintaining a manageable enterprise size relative to large-cap healthcare peers.
Salud financiera
The company reported revenue of $822.31M for the trailing twelve months, yet it generated a net income of -$92,192,000, revealing a substantial gap between top-line sales and bottom-line profitability. This significant divergence highlights a challenging cost structure where operating expenses, likely driven by research and development or regulatory compliance costs, heavily outweigh gross profits. Despite the net loss, the entity reported an EBITDA of -$6,147,000, suggesting that while operational cash generation before interest and taxes is negative, it is less severe than the net loss due to non-operating expenses. Crucially, the company maintains a free cash flow of $20.53M, which provides essential financial flexibility to fund operations and capital expenditures without immediate reliance on external equity financing. Profitability analysis shows a gross margin of 68.8%, indicating high efficiency in manufacturing and pricing power, but this is offset by an operating margin of -1.3% and a profit margin of -11.2%, signaling that overhead costs are eroding the majority of gross earnings. On the balance sheet, Orthofix holds $82.03M in cash against $203.85M in total debt, resulting in a debt-to-equity ratio of 45.30, which characterizes the company as a leveraged entity with a conservative cash position relative to its obligations. Liquidity is robust with a current ratio of 2.44, indicating that the company holds more than double the current assets necessary to cover its short-term liabilities. Finally, the return on equity stands at -19.3% and the return on assets at -4.9%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and the total asset base.
Evaluación de valoración
Valuation metrics present a mixed picture with a P/E ratio (TTM) listed as N/A due to the net loss, while the forward P/E is 13.45, implying that the market expects earnings normalization or significant improvement in the coming fiscal year. The price-to-book ratio of 1.02 suggests that the stock trades at a value nearly equal to its book value, indicating no significant market premium or discount relative to the net asset value of the company. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.56 and an EV/EBITDA of -94.92, the latter reflecting the current unprofitability which distorts the traditional multiple comparison. The stock has exhibited volatility within a trading range defined by a 52-week high of $17.00 and a 52-week low of $10.24, with the current market price situated significantly below the yearly peak. Risk assessment is aided by a beta of 0.78, which indicates that the stock's price movements are less volatile than the broader market, offering a degree of stability often found in defensive healthcare sectors despite the underlying financial losses.
Growth & Income
Growth metrics show a revenue growth of 2.0% year-over-year, while earnings growth is N/A given the reported losses, illustrating that top-line expansion is not yet translating into bottom-line profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings are theoretically available for reinvestment rather than distribution to shareholders. This lack of a payout ratio implies that Orthofix Medical Inc. prioritizes reinvesting its resources into product development, market expansion, or debt reduction to address the negative net income situation. Consequently, the overall growth and income profile is defined by modest revenue expansion coupled with a complete absence of current income distribution, relying on future operational improvements to generate sustainable profits.